Pathos raises $237 million as Bristol Myers Squibb backs Alzheimer’s partnership
Pathos announced on Friday that it was raising $237 million in a Series E round led by Bristol Myers Squibb, bringing the AI-driven drug development company’s valuation to approximately $3 billion. The deal expands Pathos beyond oncology into neurological…
